STAT1 T749 Phosphorylation Modulation for Inflammatory Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The role of Stat1 in inflammatory responses, particularly its noncanonical phosphorylation at threonine 749, has not been well understood, and existing treatments for inflammatory diseases like sepsis, colitis, and systemic lupus erythematosus are inadequate.
Innovation Solution
Development of therapeutic agents that inhibit or promote the phosphorylation of threonine 749 in human STAT1, using compounds that target protein kinases such as TBK1 and IKKβ, and antibodies that selectively bind to phosphorylated STAT1, along with screening methods to identify these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional JAK-STAT pathway inhibitors are used, then canonical STAT1 phosphorylation is inhibited, but noncanonical phosphorylation at threonine 749 by IKKβ/TBK1 remains active, leading to insufficient control of inflammatory responses
Solution Approach 1:
The invention segments the STAT1 regulation into two independent control mechanisms: canonical JAK-mediated phosphorylation (responsible for antiviral responses) and noncanonical IKKβ/TBK1-mediated phosphorylation at threonine 749 (responsible for inflammatory responses). This segmentation allows selective inhibition of each pathway using specific compounds, enabling precise control of different STAT1 functions without interfering with the other pathway.
Solution Approach 2:
The invention introduces specific intermediary compounds that target the IKKβ and TBK1 kinases as mediators between LPS stimulation and STAT1 phosphorylation. These compounds (such as those inhibiting IKKβ or TBK1) act as intermediate agents that block the noncanonical phosphorylation pathway, thereby controlling inflammatory responses independently of the canonical JAK-STAT pathway.
2Object-affected harmful factors
If STAT1 is completely inhibited, then inflammatory responses are suppressed, but antiviral defenses are compromised
Solution Approach 1:
The invention applies local quality by differentiating the functional domains of STAT1: the canonical pathway (involving JAKs and tyrosine phosphorylation) is maintained for antiviral defense, while the noncanonical pathway (involving IKKβ/TBK1 and threonine 749 phosphorylation) is selectively inhibited to reduce inflammatory damage. This localized differentiation of pathway inhibition allows simultaneous preservation of antiviral function and suppression of harmful inflammation.
Solution Approach 2:
Instead of inhibiting STAT1 globally to treat inflammation (which would harm antiviral defense), the invention inverts the approach by selectively inhibiting the upstream kinases (IKKβ/TBK1) that cause harmful noncanonical phosphorylation. This inverted strategy targets the source of inflammatory damage while preserving the canonical antiviral pathway's ability to function through JAK-mediated STAT1 activation.
3Productivity
If existing therapeutic agents are used for sepsis and colitis, then some symptomatic relief is achieved, but disease-specific mechanisms are not adequately targeted
Solution Approach 1:
The invention applies parameter changes by developing compounds that specifically alter the phosphorylation state of STAT1 at threonine 749, rather than using general STAT1 inhibitors. By changing the specific parameter of phosphorylation (from tyrosine to threonine, and from JAK-mediated to IKKβ/TBK1-mediated), the therapy becomes tailored to the specific pathophysiology of sepsis and colitis, improving both effectiveness and disease-specific targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents effectively treat inflammatory diseases by modulating STAT1 activity, providing novel treatments for sepsis, colitis, and systemic lupus erythematosus, with potential for improved patient outcomes.
Implementation Method 1
threonine 749 is a potential phosphorylation site of STAT1 TAD activated by IKK-related kinase β (IKKβ) in lipopolysaccharide (LPS)-stimulated human macrophages
Implementation Method 2
an antibody capable of binding to human STAT1 phosphorylated at threonine at position 749
Data Source
AI summary
The present invention provides a therapeutic agent for sepsis and/or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and/or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.